Hydroxetamine (HXE)
Hydroxetamine (HXE) is an arylcyclohexylamine dissociative in the ketamine/methoxetamine family that appeared as a research chemical in the late 2010s. It is an NMDA receptor antagonist producing dose-dependent dissociation and anaesthesia. Human information is anecdotal, and bladder toxicity is a plausible concern shared with related ketamine-type dissociatives.
01 Overview
Hydroxetamine is structurally related to methoxetamine and the wider arylcyclohexylamine dissociatives. It has no clinical characterisation and is known from user reports as a moderately potent dissociative used orally or insufflated.
Effects follow the class pattern of dose-dependent dissociation, analgesia and anaesthesia. Because ketamine and several of its analogues cause urinary-tract and bladder toxicity with heavy or frequent use, this remains a plausible risk for HXE, alongside dissociation, ataxia and redosing-related overdose.
02 Mechanism
Non-competitive NMDA receptor antagonist (open-channel blocker); an arylcyclohexylamine in the methoxetamine/ketamine structural family.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Light | 8–20 mg | Insufflated | Faster onset; poorly characterised. |
| Light | 10–20 mg | Oral | Estimated from anecdote. |
| Common | 20–40 mg | Oral | Poorly characterised; caution. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| DissociationDetachment, depersonalisation and derealisation. | Anecdotal | ||
| AnalgesiaReduced pain perception at higher doses. | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Ataxia and loss of coordinationUnsteady gait and impaired motor control with fall risk. | Moderate | Very common | Anecdotal | |
| Bladder and urinary-tract toxicityCystitis-type bladder damage seen with ketamine and analogues may extend to HXE with frequent heavy use. | Severe | Plausible with heavy use | Unconfirmed |